Industry Overview - The global weight loss drug market is projected to grow from $15 billion in 2024 to $150 billion by 2035, indicating a significant expansion opportunity [1] - Currently, 11% of the global eligible population of 1.3 billion people are using weight-loss drugs, with 20% in the U.S. and 10% in other countries [2] - The market growth is attributed to expanded supply, clinical benefits for other diseases, and increasing employer drug coverage [2] Market Dynamics - The obesity drug market is transitioning from a novelty phase to a focus on execution, scale, cost-control, and ecosystem management [5] - Industry experts compare the current weight-loss drug market to the smartphone market of 2015-2016, suggesting a maturation phase [4] - There is increasing pressure on drug manufacturers to deliver weight-loss drugs at scale and manage costs effectively [6] Company Insights Novo Nordisk - Year-to-date performance shows a decline of 45.49%, with a significant drop of 55% over the past year [9] - The company has reached an agreement to expand consumer access to GLP-1 medicines, which may enhance market position [10] - Novo is offering weight-loss drugs at a direct-to-consumer price of $349 per month, with a dividend yield of 2.52% [11] Eli Lilly - Year-to-date performance indicates a decline of 36.1%, but the company is experiencing rapid growth in its obesity drug portfolio [12] - Eli Lilly's obesity drugs generated $10.1 billion in Q3 2025, up from $4.3 billion in Q3 2024, with a projected peak revenue of $101 billion [12] - The company has a strong financial outlook with $59.4 billion in revenues and a three-year expected growth rate of 17.1% annually [13] Viking Therapeutics - Year-to-date performance shows a decline of 17.20%, with a market cap of $3 billion [14] - The company is awaiting clearance for its phase three trials for VK2735, which has shown strong growth potential [14] - Viking is positioned favorably for potential partnerships or acquisitions due to its strong data and small-cap valuation [15]

Core Insights - Novo Nordisk (NVO) is facing a significant disconnect between its market capitalization and actual business fundamentals, indicating potential mispricing in the market [1] Company Analysis - The company is not experiencing any decline in its prospects, suggesting that the fundamentals remain strong despite market perceptions [1]

Novo Nordisk was at the forefront of the weight-loss injection boom but has been struggling with increased competition. Looking to regain its edge, Novo has cut its US prices. Here's what to know. https://t.co/p6IIIWbUl1 ...

Core Insights - Digital health company Waltz Health has launched a program to provide popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, aiming to bypass traditional drug sales channels [1] Company Summary - Waltz Health is focusing on direct sales of weight-loss medications, which may disrupt the conventional pharmaceutical distribution model [1] - The initiative targets employers, potentially expanding access to these medications for employees [1] Industry Summary - The move reflects a growing trend in the digital health sector to streamline access to medications and enhance employer-sponsored health programs [1] - The partnership with major pharmaceutical companies like Novo Nordisk and Eli Lilly indicates a significant shift in how weight-loss drugs are marketed and distributed [1]

Core Insights - Ozempic has emerged as a leading weight loss drug, generating significant sales and market interest [1] Sales Performance - Projected sales for Ozempic are expected to reach $17 billion in 2024 [1] - In the first half of 2025, sales are anticipated to exceed $10 billion [1] Manufacturer Impact - The success of Ozempic is beneficial for its manufacturer, Novo Nordisk A/S [1]

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient Compensat... ...

Eli Lilly and Novo Nordisk plan to start selling their popular obesity shots to employers through a new approach that would bypass traditional drug sales channels in an effort to expand access to the costly weight-loss medicines. https://t.co/wywq3jyGQ9 ...

Core Insights - Seeking Alpha welcomes a new contributing analyst, Joseph Elijah, who aims to share investment ideas and insights with serious investors [1] Group 1: Analyst Background - The new analyst has over a decade of experience in quantitative finance, risk management, and derivatives trading across global financial markets [2] - The analyst holds a Master's degree in Quantitative Finance from the Wharton School and began their career at Morgan Stanley, focusing on model risk management [2] - After five years at Morgan Stanley, the analyst worked at DRW for six years, initially as a Business Analyst in FICC Options and later as a Quantitative Researcher in Israel [2] Group 2: Investment Philosophy - The analyst has transitioned to managing a personal investment portfolio and aims to share knowledge and investment philosophy online [2] - Seeking Alpha is identified as the preferred platform for connecting with serious investors who value in-depth analysis [2]

Core Insights - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] - The mission of Allka Research includes sharing knowledge and analyses through Seeking Alpha, fostering a community of informed investors [1] Company Overview - Allka Research is recognized for its dedication to uncovering lucrative investment opportunities [1] - The firm aims to empower individuals financially by providing thought-provoking analyses and informed perspectives [1] - The company seeks to demystify investing, inspiring confidence among its readers [1]

Core Insights - The article discusses the author's perspective on various stocks, aiming to provide contrasting views based on their background and experience [1]. Group 1 - The author expresses interest in a wide range of stocks and aims to share unique insights with other investors [1]. - The analysis is intended for informational purposes and emphasizes the importance of conducting personal research before making investment decisions [3]. - There is a disclosure regarding the author's potential future position in NVO, indicating a possible beneficial long position within 72 hours [2].